Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genom-wide expression study of cMoP and iMoP from murine bone marrow

ABSTRACT: Genom-wide expression study of cMoP and iMoP from murine bone marrow

PROVIDER: PRJNA482151 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Genom-wide expression study of cMoP and monocytes from murine bone marrow compared to their differentiated descendants

Project description:Genom-wide expression study of cMoP and monocytes from murine bone marrow compared to their differentiated descendants

| PRJNA482147 | ENA

Genom-wide expression study of cMoP and iMoP from murine bone marrow

Project description:We defined iMoP as a new precursor subset in murine bone marrow. The aim of this expression analysis was the identification of transcriptional differences between iMoP and their progeny cMoP.

2021-01-04 | GSE117460 | GEO

Genome-wide analysis of chromatin landscape in murine bone marrow derived eosinophils

Project description:Genome-wide analysis of chromatin landscape in murine bone marrow derived eosinophils

| PRJNA605431 | ENA

Gene expression profile of murine bone marrow endosteal populations

Project description:This SuperSeries is composed of the following subset Series: GSE17569: Gene expression profile of murine bone marrow endosteal populations (1) GSE17570: Gene expression profile of murine bone marrow endosteal populations (2) Refer to individual Series

2010-08-10 | E-GEOD-17597 | biostudies-arrayexpress

scRNA-seq of murine bone and marrow cells

Project description:scRNA-seq of murine bone and marrow cells

| PRJNA994550 | ENA

CITE-seq of murine bone and marrow cells

Project description:CITE-seq of murine bone and marrow cells

| PRJNA994542 | ENA

Identification of adipo-osteoprogenitors in murine bone marrow

Project description:Identification of adipo-osteoprogenitors in murine bone marrow

| PRJNA1064919 | ENA

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Project description:RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.

| 2004880 | ecrin-mdr-crc

RNASeq analysis of murine bone marrow derived macrophages (BMDMs)

Project description:RNASeq analysis of murine bone marrow derived macrophages (BMDMs)

| PRJNA754194 | ENA

Low dose ruxolitinib plus cyclosporine to treat murine immune-mediated bone marrow failure

Project description:Background and methods: Ruxolitinib (RUX), a Jak1/2 inhibitor, has been reported to attenuate murine bone marrow failure recently. Its potential toxocicty of anemia and thrombocytopenia in human remains a concern. To minimize its potential toxoxicity, we tested therapeutic effectsof low dose ruxolitinib plus cyclosporine in murine model of immune-mediated bone marrow failure. Bone marrow CD8 and CD4 T cells were sorted from treated or untreated bone marrow failure mice. RNA-Seq and analysis was performed using SMART-Seq mRNA LP Kit (Takara) and the Illumina Novaseq6000, according to the Institute's protocols. Results: low dose of ruxolitinib plus cyclosporine improved pancytopenia and BM cellularity and decreased BM T cell infiltration in bone marrow failure mice. RNA sequencing demonstrated that low dose of ruxolitinib plus cyclosporine suppressed immune-related pathways in bone marrow infiltrated CD8 T cells and MHC-II expression in CD4 T cells compared with untreated mice. Conclusion: Our results demonstrate that low dose of ruxolitinib plus cyclosporine remains the efficacy in attenuation of disease and extending survival of immune-mediated bone marrow failure mice.

2024-05-08 | GSE240864 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data